arrow
G

Grzegorz S. Nowakowski

Mayo Clinic
H指数:64
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Autologous Stem Cell Transplant Consolidation Is Associated With Improved Overall Survival in Angioimmunoblastic T-Cell Lymphoma: A Real-World National Cancer Database Study

自体干细胞移植巩固治疗与血管免疫母细胞性T细胞淋巴瘤患者总生存期改善相关:一项真实世界国家癌症数据库研究

2026-09-300
PRE
Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study

套细胞淋巴瘤在24个月无事件生存期(EFS24)后的长期生存和特定病因死亡率:一项国际多队列研究

2026-09-220
OAAI
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study

大B细胞淋巴瘤二线治疗的治疗模式与疗效:LEO CReWE研究的结果

2026-07-230
OA
Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis

新型疗法时代外周T细胞淋巴瘤的生存趋势揭示其未满足的需求:一项国家癌症数据库分析

2026-06-030
OAAI
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience

慢性淋巴细胞白血病(CLL)患者中Richter转化的中枢神经系统受累:梅奥诊所的经验

2026-01-070
OAAI
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma

二线CD19 CAR-T治疗与铂类挽救疗法及自体干细胞移植治疗原发纵隔B细胞淋巴瘤的比较

2026-01-010
OA
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients

治疗策略与临床结局在原发结直肠MALT淋巴瘤中的研究:一项纳入66例患者的单中心回顾性研究

2025-12-010
OA
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION

复发/难治性原发性中枢神经系统淋巴瘤患者对新型EMAVUSERTIB(IRAK4I)和BTKI联合治疗反应的遗传突变谱和中枢神经系统药代动力学分析

2025-11-010
OAAI
PRELIMINARY SAFETY AND EFFICACY OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS

初步安全性及有效性:Emavusertib (CA-4948) 联合 Ibrutinib 在复发/难治性原发性中枢神经系统淋巴瘤患者中的应用

2025-11-010
OAAI
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study

ctDNA动力学证明了tafasitamab + R-CHOP +/- lenalidomide的快速治疗反应,并能预测弥漫性大B细胞淋巴瘤的结局:First-MIND 1b期研究结果

Leukemia
IF13.4
2025-10-270
OA
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma

整合基因组学与精细的细胞起源亚型划分,区分了弥漫性大B细胞淋巴瘤中特定亚型的治疗抵抗和复发机制。

2025-07-120
OAAI